Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nicoletti, F.
Right arrow Articles by Reggio, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nicoletti, F.
Right arrow Articles by Reggio, A.
Neurology 2001;57:342-344
© 2001 American Academy of Neurology
Brief Communications

Increased serum levels of interleukin-18 in patients with multiple sclerosis

F. Nicoletti, MD, R. Di Marco, MD, PhD, K. Mangano, F. Patti, MD, E. Reggio, MD, A. Nicoletti, MD, K. Bendtzen, MD, Prof; and A. Reggio, MD, Prof

From the Institute of Microbiology (Dr. F. Nicoletti), University of Milan Bicocca; Department of Microbiological and Gynecologic Sciences (Drs. Di Marco and Mangano) and Institute of Neurology (Drs. Patti, E. Reggio, A. Nicoletti, and A. Reggio), University of Catania, Italy; and Institute for Inflammation Research (Dr. Bendtzen), Rigshospitalet University Hospital, Copenhagen, Denmark.

Address correspondence and reprint requests to Dr. Ferdinando Nicoletti, Via Luigi Sturzo n. 3, 95021, Cannizzaro, Catania, Italy.

Serum but not CSF concentrations of the interferon-{gamma}-inducing cytokine interleukin (IL)-18 were significantly augmented in patients with MS as compared to both healthy controls and patients with other neurologic diseases. Patients with MS with secondary chronic progressive disease had significantly higher serum levels than those with relapsing remitting MS. In the latter group, IL-18 levels were higher in patients with acute exacerbation as compared to those with stable disease.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. Omoto, K. Tokime, K. Yamanaka, K. Habe, T. Morioka, I. Kurokawa, H. Tsutsui, K. Yamanishi, K. Nakanishi, and H. Mizutani
Human Mast Cell Chymase Cleaves Pro-IL-18 and Generates a Novel and Biologically Active IL-18 Fragment
J. Immunol., December 15, 2006; 177(12): 8315 - 8319.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Aranami, S. Miyake, and T. Yamamura
Differential Expression of CD11c by Peripheral Blood NK Cells Reflects Temporal Activity of Multiple Sclerosis
J. Immunol., October 15, 2006; 177(8): 5659 - 5667.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
C A B. Hashemi, Y C. Zang, J A Arbona, J A Bauerle, M L Frazer, H Lee, L Flury, E S Moore, M C Kolar, R Y Washington, et al.
Serum immunologic markers in multiple sclerosis patients on continuous combined therapy with beta-interferon 1a, prednisone and azathioprine
Multiple Sclerosis, September 1, 2006; 12(5): 652 - 658.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.